Immix Biopharma, Inc. IMMX Net Operating Loss Carryforwards
Net Operating Loss Carryforwards at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwards.
The official record: Immix Biopharma, Inc.’s 10-K/A, filed March 27, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s net operating loss carryforwards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s net operating loss carryforwards?
- Immix Biopharma, Inc. (IMMX) reported net operating loss carryforwards of $16.19K in Q4 2025.
- How has Immix Biopharma, Inc.'s net operating loss carryforwards changed year-over-year?
- Immix Biopharma, Inc.'s net operating loss carryforwards decreased by 99.4% year-over-year, from $2.53M to $16.19K.
- What is the long-term trend for Immix Biopharma, Inc.'s net operating loss carryforwards?
- Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s net operating loss carryforwards has grown at a -3.6% compound annual growth rate (CAGR), from $19.43K to $16.19K.
- What does net operating loss carryforwards mean?
- These are tax assets representing losses that can be used to reduce taxable income in future periods. They provide a potential future tax shield, improving cash flow by lowering future tax payments. Investors monitor these to estimate the duration and magnitude of potential tax savings.